Metachromatic Leukodystrophy ([MLD](/diseases/metachromatic-[leukodystrophy](/diseases/leukodystrophy)))

Metachromatic Leukodystrophy ([MLD](/diseases/metachromatic-[leukodystrophy](/diseases/leukodystrophy)))

Introduction

Metachromatic [leukodystrophy](/diseases/leukodystrophy) ([MLD](/diseases/metachromatic-[leukodystrophy](/diseases/leukodystrophy))) is a rare autosomal recessive [lysosomal storage disorders](/diseases/lysosomal-storage-disorders) disorder caused by deficiency of arylsulfatase A ([ARSA](/genes/arsa)), leading to accumulation of [sulfatides](/mechanisms/sulfatide-metabolism) (galactosylceramide sulfates) in the [white matter](/brain-regions/white-matter) of the central nervous system and peripheral nerves. This progressive de[myelin](/mechanisms/[demyelination](/mechanisms/demyelination))ating disease primarily affects children but can present at any age, causing severe neurological decline and premature death.[@van2022]

Classification

Clinical Forms

| Form | Age of Onset | Progression | Clinical Features |
|------|--------------|-------------|-------------------|
| Late Infantile | 1-2 years | Rapid | Motor regression, gait disturbance, seizures |
| Juvenile | 3-16 years | Variable | Cognitive decline, motor symptoms |
| Adult | >16 years | Slow | Psychiatric symptoms, dementia |

Carrier Frequency

• Incidence: 1 in 40,000 - 1 in 160,000 (varies by population)
• Carrier Frequency: ~1 in 40-80 in general population
• Founder Mutations: Common in Amish, Mennonite, Portuguese populations

Pathogenesis

[ARSA](/genes/arsa) Deficiency

...

Metachromatic Leukodystrophy ([MLD](/diseases/metachromatic-[leukodystrophy](/diseases/leukodystrophy)))

Introduction

Metachromatic [leukodystrophy](/diseases/leukodystrophy) ([MLD](/diseases/metachromatic-[leukodystrophy](/diseases/leukodystrophy))) is a rare autosomal recessive [lysosomal storage disorders](/diseases/lysosomal-storage-disorders) disorder caused by deficiency of arylsulfatase A ([ARSA](/genes/arsa)), leading to accumulation of [sulfatides](/mechanisms/sulfatide-metabolism) (galactosylceramide sulfates) in the [white matter](/brain-regions/white-matter) of the central nervous system and peripheral nerves. This progressive de[myelin](/mechanisms/[demyelination](/mechanisms/demyelination))ating disease primarily affects children but can present at any age, causing severe neurological decline and premature death.[@van2022]

Classification

Clinical Forms

| Form | Age of Onset | Progression | Clinical Features |
|------|--------------|-------------|-------------------|
| Late Infantile | 1-2 years | Rapid | Motor regression, gait disturbance, seizures |
| Juvenile | 3-16 years | Variable | Cognitive decline, motor symptoms |
| Adult | >16 years | Slow | Psychiatric symptoms, dementia |

Carrier Frequency

• Incidence: 1 in 40,000 - 1 in 160,000 (varies by population)
• Carrier Frequency: ~1 in 40-80 in general population
• Founder Mutations: Common in Amish, Mennonite, Portuguese populations

Pathogenesis

[ARSA](/genes/arsa) Deficiency

[MLD](/diseases/metachromatic-[leukodystrophy](/diseases/leukodystrophy)) results from mutations in the [ARSA](/genes/arsa) gene located on chromosome 22q13.31:[@van2022]

Molecular Mechanisms

Sulfatide Accumulation: [ARSA](/genes/arsa) normally degrades [sulfatides](/mechanisms/sulfatide-metabolism); deficiency causes toxic buildup

Oligodendrocyte Death: Sulfatides are toxic to [myelin](/mechanisms/[demyelination](/mechanisms/demyelination))-producing cells

Myelin Instability: Accumulated [sulfatides](/mechanisms/sulfatide-metabolism) disrupt [myelin](/mechanisms/[demyelination](/mechanisms/demyelination)) lipid organization

Axonal Degeneration: Secondary to de[myelin](/mechanisms/[demyelination](/mechanisms/demyelination))ation

Pseudo-[ARSA](/genes/arsa) Deficiency

• [ARSA](/genes/arsa)-Pseudodeficiency: Common variant with reduced but not absent enzyme activity
• No Clinical Symptoms: Usually benign; can complicate diagnosis

Genetic Factors

[ARSA](/genes/arsa) Mutations

• Missense Mutations: Most common; genotype-phenotype correlation variable
• Nonsense Mutations: Often cause severe (infantile) form
• Splice Site Mutations: Can cause frameshift and premature termination
• Large Deletions: Less common, severe phenotype

Common Mutations by Population

| Population | Common Mutation | Form |
|------------|-----------------|------|
| Amish | c.526C>T (p.Arg176*) | Infantile |
| European | c.459+1G>A (splice site) | Infantile |
| Portuguese | c.542T>G (p.Leu181Arg) | Juvenile |
| Turkish | c.643C>T (p.Arg215Cys) | Variable |

Genotype-Phenotype Correlation

• Two Null Alleles: Severe infantile form
• One Null + One Missense: Variable, often juvenile
• Two Missense: Usually adult onset, milder

Clinical Features

Symptoms

Infantile Form (Most Common)

• Motor Regression: Loss of previously acquired motor skills
• Hypotonia: Progressive muscle weakness
• Ataxia: Gait disturbance, coordination loss
• Seizures: Often generalized tonic-clonic
• Optic Atrophy: Visual impairment
• Peripheral Neuropathy: Reduced reflexes, distal weakness

Juvenile Form

• Cognitive Decline: Progressive intellectual disability
• Behavioral Changes: Attention deficit, personality changes
• Motor Symptoms: Gait disturbance, spasticity
• Speech Impairment: Dysarthria, eventual loss

Adult Form

• Psychiatric Symptoms: Depression, psychosis, schizophrenia-like
• Cognitive Decline: Progressive dementia
• Motor Symptoms: Often milder than childhood forms
• Peripheral Neuropathy: May be presenting feature

Diagnostic Markers

| Marker | Finding |
|--------|---------|
| [ARSA](/genes/arsa) Enzyme Activity | Deficient in leukocytes/fibroblasts |
| MRI Brain | Tiger stripe pattern, diffuse [white matter](/brain-regions/white-matter) T2 hyperintensity |
| Nerve Conduction | De[myelin](/mechanisms/[demyelination](/mechanisms/demyelination))ating peripheral neuropathy |
| Urine Sulfatides | Elevated (elevated sulfatide excretion) |
| Genetic Testing | [ARSA](/genes/arsa) mutation analysis |

MRI Characteristics

• Tiger Stripe Pattern: Radial stripes in periventricular [white matter](/brain-regions/white-matter)
• Diffuse De[myelin](/mechanisms/[demyelination](/mechanisms/demyelination))ation: Confluent T2 hyperintensities
• Posterior Predominance: Often more severe in posterior brain regions
• Cerebellar Atrophy: In later stages
• Sparing of U-Fibers: Relative preservation initially

Relationship to Neurodegeneration

Shared Mechanisms with Other Disorders

Lysosomal Dysfunction: Common with other LSDs and some forms of AD/PD

Myelin Breakdown: Similar patterns to other leukodystrophies

Oxidative Stress: Elevated in [MLD](/diseases/metachromatic-[leukodystrophy](/diseases/leukodystrophy)) and neurodegenerative diseases

Neuroinflammation: Glial activation in de[myelin](/mechanisms/[demyelination](/mechanisms/demyelination))ated regions

Models of Neurodegeneration

[MLD](/diseases/metachromatic-[leukodystrophy](/diseases/leukodystrophy)) serves as a model for understanding:

• Lysosomal storage diseases
• De[myelin](/mechanisms/[demyelination](/mechanisms/demyelination))ating disorders
• White matter degeneration
• Gene therapy approaches

Treatment Approaches

Current Management[@farrera2024]

| Treatment | Indication | Status |
|-----------|------------|--------|
| Hematopoietic Stem Cell Transplant | Early disease | Established |
| Enzyme Replacement Therapy | All forms | In development |
| Gene Therapy | Early disease | FDA approved (Libmeldy) |
| Substrate Reduction Therapy | All forms | Investigational |
| Supportive Care | All stages | Standard |

Libmeldy (Atidarsagene Autotemcel)

• Type: Autologous [gene therapy](/mechanisms/gene-therapy-neurodegeneration)
• Mechanism: Ex vivo [ARSA](/genes/arsa) gene addition to [hematopoietic stem cell transplantation](/therapeutics/hematopoietic-stem-cell-transplantation)s
• Efficacy: Preserves motor function in early infantile [MLD](/diseases/metachromatic-[leukodystrophy](/diseases/leukodystrophy))
• Approval: FDA approved (2024), EMA approved (2020)

Clinical Trials (2024-2025)

[AAV gene therapy](/mechanisms/aav-gene-therapy-vectors-neurodegeneration) Vector Gene Therapy: Direct CNS delivery

Novel ERT: Brain-penetrant [enzyme replacement therapy](/therapeutics/enzyme-replacement-therapy)

Substrate Reduction Therapy: Reduce sulfatide production

Small Molecule Therapies: Chaperone proteins

Supportive Care

• Physical Therapy: Maintain mobility
• Occupational Therapy: Adaptive equipment
• Speech Therapy: Communication support
• Seizure Management: Antiepileptic drugs
• Nutritional Support: Feeding assistance as needed

Animal Models

Mouse Models

• [ARSA](/genes/arsa)-/- Mouse: Spontaneous sulfatide accumulation
• Transgenic Models: Human [ARSA](/genes/arsa) mutations
• Phenotype: Progressive de[myelin](/mechanisms/[demyelination](/mechanisms/demyelination))ation, motor deficits

Applications

• Gene therapy testing
• ERT development
• Biomarker studies
• Natural history studies

Recent Research (2024-2025)

• Gene Therapy Outcomes: Long-term follow-up of Libmeldy shows sustained benefit[@farrera2024]
• Newborn Screening: Implementation increasing early detection
• Biomarker Development: Neurofilament light chain as disease progression marker
• Natural History: Better understanding of genotype-phenotype correlations

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References

[van Rappard et al., Metachromatic Leukodystrophy (Lancet Neurol, 2022) (2022)](/[DOI:10.1016/S1474-4422(22](https://doi.org/10.1016/S1474-4422(22))

[Farrera et al., Gene Therapy for [MLD](/diseases/metachromatic-[leukodystrophy](/diseases/leukodystrophy)) (Mol Ther, 2024) (2024)](/[DOI:10.1016/j.ymthe.2024.01.012](https://doi.org/10.1016/j.ymthe.2024.01.012))